Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975535 | 0.79 | ADORA3 (0.66) | CYP3A4HSD17B10ADORA3MAOACYP2D6 | |
| SCHEMBL6994969 | 0.78 | ALDH2 (0.56) | PTPN1CYP3A4HSD17B10ADORA3MAOA | |
| SCHEMBL8440887 | 0.76 | PTPN1 (0.53) | PTPN1CYP3A4HSD17B10ADORA3MAOA | |
| SCHEMBL29598759 | 0.75 | ABCG2 (0.64) | PTPN1CYP3A4HSD17B10ADORA3MAOA | |
| SCHEMBL1301705 | 0.74 | CYP3A4 (0.62) | PTPN1CYP3A4HSD17B10ADORA3MAOA | |
| SCHEMBL8494597 | 0.70 | KDM4E (0.63) | CYP3A4MAOACYP2C19ALDH1A1KDM4E | |
| SCHEMBL600311 | 0.70 | KDM4E (0.58) | PTPN1CYP3A4HSD17B10MAOACYP2D6 | |
| SCHEMBL29597830 | 0.70 | PTPN1 (1.00) | PTPN1CYP3A4HSD17B10CYP2D6CYP2C19 | |
| Bergapten SCHEMBL29529284 | 0.69 | ALDH1A1 (1.00) | CYP3A4HSD17B10ADORA3MAOACYP2D6 | |
| Bergapten SCHEMBL50066 | 0.69 | ALDH1A1 (1.00) | CYP3A4HSD17B10ADORA3MAOACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7350331-B1 | Method for producing metabolites from plants cultivated in soil-less medium | INSTITUT NATIONAL POLYTECHNIQUE DE LORRAINE (INPL) (FR) | 2008-04-01 | — | — | US | disclosed |
| EP-1465590-B1 | MICELLE COMPOSITIONS CONTAINING PEGYLATED PHOSPHOLIPIDS AND A PHOTOSENSITIZER | UNIV ALBERTA (CA) | 2008-03-26 | — | — | EP | disclosed |
| US-7090691-B2 | Photodynamic therapy for the treatment of hair loss | QLT INC. (CA) | 2006-08-15 | — | — | US | disclosed |
| EP-1465590-A2 | MICELLE COMPOSITIONS CONTAINING PEGYLATED PHOSPHOLIPIDS AND A PHOTOSENSITIZER | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2004-10-13 | — | — | EP | disclosed |
| EP-1443964-A1 | PHOTODYNAMIC THERAPY FOR THE TREATMENT OF HAIR LOSS | QLT Inc. (CA) | 2004-08-11 | — | — | EP | disclosed |
| EP-1227714-B1 | METHOD FOR PRODUCING METABOLITES FROM PLANTS CULTIVATED IN SOIL-LESS MEDIUM | LORRAINE INST NAT POLYTECH (FR) | 2004-05-06 | — | — | EP | disclosed |
| US-20040015214-A1 | Photodynamic therapy for the treatment of hair loss | QLT INC. (CA) | 2004-01-22 | — | — | US | disclosed |
| US-20040013717-A1 | PEG-lipid containing formulations | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2004-01-22 | — | — | US | disclosed |
| WO-2003059309-A1 | COMPOSITION BASED ON 5,7 DMC AND/OR BERGAMOTTIN | CHAPELLE ANDRE (BE) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003039596-A1 | PHOTODYNAMIC THERAPY FOR THE TREATMENT OF HAIR LOSS | QLT INC. (CA) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003037295-A2 | MICELLE COMPOSITIONS CONTAINING PEGYLATED PHOSPHOLIPIDS AND A PHOTOSENSITIZER | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2003-05-08 | — | — | WO | disclosed |
| EP-1227714-A1 | METHOD FOR PRODUCING METABOLITES FROM PLANTS CULTIVATED IN SOIL-LESS MEDIUM | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) (FR) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001033942-A1 | METHOD FOR PRODUCING METABOLITES FROM PLANTS CULTIVATED IN SOIL-LESS MEDIUM | INSTITUT NATIONAL POLYTECHNIQUE DE LORRAINE (FR) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040013717-A1 | PEG-lipid containing formulations | PHOSPHO1, PTDSS2, PLTP | PTPN1 1269/4885CYP3A4 967/4885HSD17B10 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.